Literature DB >> 17883282

Translating efficacy into effectiveness in antiretroviral therapy: beyond the pill count.

Courtney V Fletcher1.   

Abstract

Durable and sustained suppression of HIV replication can be achieved as demonstrated in several recent clinical trials of antiretroviral (ARV) regimens. However, the efficacy demonstrated in the experimental setting does not always translate to effectiveness in the clinical setting. The frequency and number of medications (conventionally referred to as the pill count) contribute to regimen effectiveness. However, clinicians and HIV-infected patients recognise that there are several other characteristics of an ARV regimen that are equally important contributors to its effectiveness. Potency and durability, the potential for drug-drug interactions, and the occurrence of adverse events also contribute to the effectiveness and complexity of a drug regimen. A comprehensive consideration of factors associated with efficacy will optimise the translation to effectiveness for the individual infected with HIV.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17883282     DOI: 10.2165/00003495-200767140-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  41 in total

1.  An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002.

Authors:  Richard D Moore; Jeanne C Keruly; Kelly A Gebo; Gregory M Lucas
Journal:  J Acquir Immune Defic Syndr       Date:  2005-06-01       Impact factor: 3.731

2.  Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response.

Authors:  Alan Winston; Nimesh Patel; David Back; Saye Khoo; Steve Bulbeck; Sundhiya Mandalia; Anton L Pozniak; Mark Nelson; Graeme Moyle; Brian Gazzard; Marta Boffito
Journal:  J Acquir Immune Defic Syndr       Date:  2006-04-15       Impact factor: 3.731

Review 3.  Efavirenz: a review.

Authors:  Saskia M E Vrouenraets; Ferdinand W N M Wit; Jacqueline van Tongeren; Joep M A Lange
Journal:  Expert Opin Pharmacother       Date:  2007-04       Impact factor: 3.889

4.  Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART.

Authors:  S Duran; B Spire; F Raffi; V Walter; D Bouhour; V Journot; V Cailleton; C Leport; J P Moatti
Journal:  HIV Clin Trials       Date:  2001 Jan-Feb

Review 5.  Lopinavir/ritonavir (ABT-378/r).

Authors:  Nadeem A Qazi; John F Morlese; Anton L Pozniak
Journal:  Expert Opin Pharmacother       Date:  2002-03       Impact factor: 3.889

Review 6.  Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?

Authors:  Miguel Goicoechea; Brookie Best
Journal:  Expert Opin Pharmacother       Date:  2007-02       Impact factor: 3.889

7.  Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease.

Authors:  S L Catz; J A Kelly; L M Bogart; E G Benotsch; T L McAuliffe
Journal:  Health Psychol       Date:  2000-03       Impact factor: 4.267

8.  Patient preferences regarding antiretroviral therapy.

Authors:  Loren G Miller; Heather B Huffman; Beverly A Weidmer; Ron D Hays
Journal:  Int J STD AIDS       Date:  2002-09       Impact factor: 1.359

Review 9.  Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspective.

Authors:  Michael Louie; Martin Markowitz
Journal:  Antiviral Res       Date:  2002-07       Impact factor: 5.970

10.  Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence.

Authors:  Valerie E Stone; Jamie Jordan; Jerry Tolson; Robert Miller; Tom Pilon
Journal:  J Acquir Immune Defic Syndr       Date:  2004-07-01       Impact factor: 3.731

View more
  4 in total

Review 1.  Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection.

Authors:  Jamie D Croxtall; Caroline M Perry
Journal:  Drugs       Date:  2010-10-01       Impact factor: 9.546

Review 2.  Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection.

Authors:  Jamie D Croxtall
Journal:  Drugs       Date:  2012-04-16       Impact factor: 9.546

3.  Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy.

Authors:  James H Willig; Sarah Abroms; Andrew O Westfall; Justin Routman; Sunil Adusumilli; Mohit Varshney; Jeroan Allison; Ashlee Chatham; James L Raper; Richard A Kaslow; Michael S Saag; Michael J Mugavero
Journal:  AIDS       Date:  2008-10-01       Impact factor: 4.177

4.  Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil.

Authors:  Sandra W Cardoso; Paula M Luz; Luciane Velasque; Thiago Torres; Lara Coelho; Kenneth A Freedberg; Valdilea G Veloso; Rochelle P Walensky; Beatriz Grinsztejn
Journal:  AIDS Res Ther       Date:  2014-09-01       Impact factor: 2.250

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.